N-Acetylaspartate and N-Acetylaspartylglutamate in Central Nervous System Health and Disease

Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical Applications

Volumn , Issue , 2013, Pages 71-90

  Moffett, John R ^a   Ariyannur, Prasanth ^a   Arun, Peethambaran ^a   Namboodiri, Aryan M A ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Canavan's disease; MRS; NAA; NAAG; Neuropsychiatric disorders

Indexed keywords

EID: 84902229819     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-401688-0.00006-9     Document Type: Chapter

References (193)

1. Anandatheerthavarada H.K., Sepuri N.B., Biswas G., Avadhani N.G. An unusual TOM20/TOM22 bypass mechanism for the mitochondrial targeting of cytochrome P450 proteins containing N-terminal chimeric signals. Journal of Biological Chemistry 2008, 283:19769-19780.
2. Anderson K.J., Borja M.A., Cotman C.W., Moffett J.R., Namboodiri M.A., Neale J.H. N-acetylaspartylglutamate identified in the rat retinal ganglion cells and their projections in the brain. Brain Research 1987, 411:172-177.
3. Ariyannur P.S., Madhavarao C.N., Namboodiri A.M. N-acetylaspartate synthesis in the brain: mitochondria vs. microsomes. Brain Research 2008, 1227:34-41.
4. Ariyannur P.S., Moffett J.R., Madhavarao C.N., Arun P., Vishnu N., Jacobowitz D., et al. Nuclear-cytoplasmic localization of acetyl coenzyme A synthetase-1 in the rat brain. Journal of Comparative Neurology 2010, 518:2952-2977.
5. Ariyannur P.S., Moffett J.R., Manickam P., Pattabiraman N., Arun P., Nitta A., et al. Methamphetamine-induced neuronal protein NAT8L is the NAA biosynthetic enzyme: Implications for specialized acetyl coenzyme A metabolism in the CNS. Brain Research 2010, 1335:1-13.
6. Arun P., Madhavarao C.N., Hershfield J.R., Moffett J.R., Namboodiri M.A. SH-SY5Y neuroblastoma cells: a model system for studying biosynthesis of NAAG. Neuroreport 2004, 15:1167-1170.
7. Arun P., Madhavarao C.N., Moffett J.R., Hamilton K., Grunberg N.E., Ariyannur P.S., et al. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. Journal of Inherited Metabolic Disease 2010, 33:195-210.
8. Arun P., Madhavarao C.N., Moffett J.R., Namboodiri A.M. Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. Journal of Neurochemistry 2006, 98:2034-2042.
9. Arun P., Madhavarao C.N., Moffett J.R., Namboodiri A.M. Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. Journal of Neurochemistry 2008, 106:1669-1680.
10. Arun P., Moffett J.R., Namboodiri A.M. Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells. Neurochemistry International 2009, 55:219-225.
11. Avadhani N.G., Sangar M.C., Bansal S., Bajpai P. Bimodal targeting of cytochrome P450s to endoplasmic reticulum and mitochondria: the concept of chimeric signals. FEBS Journal 2011, 278:4218-4229.
12. Bacich D.J., Ramadan E., O'Keefe D.S., Bukhari N., Wegorzewska I., Ojeifo O., et al. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. Journal of Neurochemistry 2002, 83:20-29.
13. Bacich D.J., Wozniak K.M., Lu X.C., O'Keefe D.S., Callizot N., Heston W.D., et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. Journal of Neurochemistry 2005, 95:314-323.
14. Ballard F.J. Supply and utilization of acetate in mammals. American Journal of Clinical Nutrition 1972, 25:773-779.
15. Baslow M.H. A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-l-aspartic acid and N-acetyl-l-histidine, in the vertebrate nervous system. Journal of Neurochemistry 1997, 68:1335-1344.
16. Baslow M.H. Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice. Journal of Inherited Metabolic Diseases 1999, 22:99-101.
17. Baslow M.H. Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochemistry International 2002, 40:295-300.
18. Baslow M.H. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. Journal of Molecular Neuroscience 2003, 21:185-190.
19. Baslow M.H., Hrabe J., Guilfoyle D.N. Dynamic relationship between neurostimulation and N-acetylaspartate metabolism in the human visual cortex: evidence that NAA functions as a molecular water pump during visual stimulation. Journal of Molecular Neuroscience 2007, 32:235-245.
20. Baslow M.H., Hu C., Guilfoyle D.N. Stimulation-induced decreases in the diffusion of extra-vascular water in the human visual cortex: a window in time and space on mechanisms of brain water transport and economy. Journal of Molecular Neuroscience 2012, 47:639-648.
21. Becker I., Lodder J., Gieselmann V., Eckhardt M. Molecular characterization of N-acetylaspartylglutamate synthetase. Journal of Biological Chemistry 2010, 285:29156-29164.
22. Benarroch E.E. N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 2008, 70:1353-1357.
23. Blakely R.D., Robinson M.B., Thompson R.C., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. Journal of Neurochemistry 1988, 50:1200-1209.
24. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biological Psychiatry 2011, 69:495-503.
25. Burchiel K.J., Russell L.C., Lee R.P., Sima A.A. Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats. A possible mechanism of chronic diabetic neuropathic pain. Diabetes 1985, 34:1210-1213.
26. Burlina A.P., Ferrari V., Facci L., Skaper S.D., Burlina A.B. Mast cells contain large quantities of secretagogue-sensitive N-acetylaspartate. Journal of Neurochemistry 1997, 69:1314-1317.
27. Burri R., Steffen C., Herschkowitz N. N-acetyl-l-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. Developmental Neuroscience 1991, 13:403-412.
28. Bzdega T., Crowe S.L., Ramadan E.R., Sciarretta K.H., Olszewski R.T., Ojeifo O.A., et al. The cloning and characterization of a second brain enzyme with NAAG peptidase activity. Journal of Neurochemistry 2004, 89:627-635.
29. Canavan M.M. Schilder's encephalitis perioxalis diffusa. Neurology 1931, 15:299-308.
30. Cangro C.B., Namboodiri M.A., Sklar L.A., Corigliano-Murphy A., Neale J.H. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. Journal of Neurochemistry 1987, 49:1579-1588.
31. Carter R.E., Feldman A.R., Coyle J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proceedings of the National Academy of Sciences USA 1996, 93:749-753.
32. Cavaletti G., Slusher B. Regulation of glutamate synthesis via inhibition of glutamate carboxypeptidase II (GCPII): an effective method to treat central and peripheral nervous system disorders. Current Medicinal Chemistry 2012, 19:1259-1260.
33. Chakraborty G., Mekala P., Yahya D., Wu G., Ledeen R.W. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. Journal of Neurochemistry 2001, 78:736-745.
34. Choi I.Y., Gruetter R. Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat brain in vivo. Journal of Neurochemistry 2004, 91:778-787.
35. Chopra M., Yao Y., Blake T.J., Hampson D.R., Johnson E.C. The neuroactive peptide N-acetylaspartylglutamate (NAAG) is not an agonist at the mGluR3 subtype of metabotropic glutamate receptor. Journal of Pharmacology and Experimental Therapeutics 2009, 330:212-219.
36. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Developmental Neuroscience 1998, 20:271-276.
37. Collard F., Stroobant V., Lamosa P., Kapanda C.N., Lambert D.M., Muccioli G.G., et al. Molecular identification of N-acetylaspartylglutamate synthase and beta-citrylglutamate synthase. Journal of Biological Chemistry 2010, 285:29826-29833.
38. Copray S., Huynh J.L., Sher F., Casaccia-Bonnefil P., Boddeke E. Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging. Glia 2009, 57:1579-1587.
39. Costantini C., Ko M.H., Jonas M.C., Puglielli L. A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochemical Journal 2007, 407:383-395.
40. D'Adamo A.F., Yatsu F.M. Acetate metabolism in the nervous system. N-acetyl-l-aspartic acid and the biosynthesis of brain lipids. Journal of Neurochemistry 1966, 13:961-965.
41. Demougeot C., Marie C., Giroud M., Beley A. N-acetylaspartate: a literature review of animal research on brain ischaemia. Journal of Neurochemistry 2004, 90:776-783.
42. Edden R.A., Pomper M.G., Barker P.B. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magnetic Resonance in Medicine 2007, 57:977-982.
43. Edmond J., Robbins R.A., Bergstrom J.D., Cole R.A., de V.J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. Journal of Neuroscience Research 1987, 18:551-561.
44. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). Journal of Pharmacology and Experimental Therapeutics 2008, 326:209-217.
45. Feng J.F., Gurkoff G.G., Van K.C., Song M., Lowe D.A., Zhou J., et al. NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Research 2012, 1469:144-152.
46. ffrench-Mullen J.M., Koller K., Zaczek R., Coyle J.T., Hori N., Carpenter D.O. N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract. Proceedings of the National Academy of Sciences USA 1985, 82:3897-3900.
47. Flores C., Coyle J.T. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 2003, 28:1227-1234.
48. Forloni G.L., Grzanna R., Blakely R.D., Coyle J.T. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse 1987, 1:455-460.
49. Francis J.S., Strande L., Markov V., Leone P. Aspartoacylase supports oxidative energy metabolism during myelination. Journal of Cerebral Blood Flow and Metabolism 2012, 32:1736.
50. Fricker A.C., Selina Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., et al. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009, 56:1060-1067.
51. Gehl L.M., Saab O.H., Bzdega T., Wroblewska B., Neale J.H. Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. Journal of Neurochemistry 2004, 90:989-997.
52. Ghadge G.D., Slusher B.S., Bodner A., Canto M.D., Wozniak K., Thomas A.G., et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proceedings of the National Academy of SciencesUSA 2003, 100:9554-9559.
53. Goldstein F.B. Biosynthesis of N-acetyl-l-aspartic acid. Biochimica Biophysica Acta 1959, 33:583-584.
54. Goldstein F.B. The enzymatic synthesis of N-acetyl-l-aspartic acid by subcellular preparations of rat brain. Journal of Biological Chemistry 1969, 244:4257-4260.
55. Gonzalez-Toledo E., Kelley R.E., Minagar A. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurological Research 2006, 28:280-283.
56. Guan K.L., Xiong Y. Regulation of intermediary metabolism by protein acetylation. Trends in Biochemical Science 2010, 36:108-116.
57. Gullans S.R., Verbalis J.G. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annual Review.Medicine 1993, 44:289-301.
58. Hagenfeldt L., Bollgren I., Venizelos N. N-acetylaspartic aciduria due to aspartoacylase deficiency-a new aetiology of childhood leukodystrophy. Journal of Inherited Metabolic Disease 1987, 10:135-141.
59. Harris K., Lin A., Bhattacharya P., Tran T., Wong W., Ross B.D. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. N-Acetylaspartate: A Unique Neuronal Molecule In The Central Nervous System 2006, 263-273. Springer Science + Business Media, New York. J.R. Moffett, S.B. Tieman, D.R. Weinberger, J.T. Coyle, M.A. Namboodiri (Eds.).
60. Henderson Z., Salt T.E. The effects of N-acetylaspartylglutamate and distribution of N-acetylaspartylglutamate-like immunoreactivity in the rat somatosensory thalamus. Neuroscience 1988, 25:899-906.
61. Hlouchova K., Barinka C., Klusak V., Sacha P., Mlcochova P., Majer P., et al. Biochemical characterization of human glutamate carboxypeptidase III. Journal of Neurochemistry 2007, 101:682-696.
62. Jalil M.A., Begum L., Contreras L., Pardo B., Iijima M., Li M.X., et al. Reduced N-acetylaspartate levels in mice lacking Aralar, a brain-and muscle-type mitochondrial aspartate-glutamate carrier. Journal of Biological Chemistry 2005, 280:31333-31339.
63. Janson C., McPhee S., Bilaniuk L., Haselgrove J., Testaiuti M., Freese A., et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Human Gene Therapy 2002, 13:1391-1412.
64. Johnson E.C. N-acetylaspartylglutamate is not demonstrated to be a selective mGlureceptor agonist. Journal of Neurochemistry 2011, 119:896-898.
65. Jonas M.C., Pehar M., Puglielli L. AT-1 is the ER membrane acetyl-CoA transporter and is essential for cell viability. Journal of Cell Science 2010, 123:3378-3388.
66. Jones H.E., Sillito A.M. The action of the putative neurotransmitters N-acetylaspartylglutamate and l-homocysteate in cat dorsal lateral geniculate nucleus. Journal of Neurophysiology 1992, 68:663-672.
67. Kantarci K., Jack C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America 2003, 13:197-209.
68. Kaul R., Balamurugan K., Gao G.P., Matalon R. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 1994, 21:364-370.
69. Kaul R., Gao G.P., Aloya M., Balamurugan K., Petrosky A., Michals K., et al. Canavan disease: mutations among Jewish and non-jewish patients. American Journal of Human Genetics 1994, 55:34-41.
70. Kaul R., Gao G.P., Balamurugan K., Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nature Genetics 1993, 5:118-123.
71. Kaul R., Gao G.P., Matalon R., Aloya M., Su Q., Jin M., et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. American Journal of Human Genetics 1996, 59:95-102.
72. 2+ concentration in the spinal dorsal horn in an animal model of neuropathic pain. Pain 1996, 68:85-96.
73. Kitada K., Akimitsu T., Shigematsu Y., Kondo A., Maihara T., Yokoi N., et al. Accumulation of N-acetyl-l-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. Journal of Neurochemistry 2000, 74:2512-2519.
74. Klugmann M., Leichtlein C.B., Symes C.W., Serikawa T., Young D., During M.J. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Molecular Therapy 2005, 11:745-753.
75. Klugmann M., Symes C.W., Klaussner B.K., Leichtlein C.B., Serikawa T., Young D., et al. Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 2003, 14:1837-1840.
76. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. EMBO Journal 2000, 19:1176-1179.
77. Kumar S., Biancotti J.C., Matalon R., de V.J. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. Journal of Neuroscience Research 2009, 87:3415-3427.
78. Kumar S., Mattan N.S., de V.J. Canavan disease: a white matter disorder. Mental Retardation Developmental Disabilities Research Review 2006, 12:157-165.
79. Kumar S., Sowmyalakshmi R., Daniels S.L., Chang R., Surendran S., Matalon R., et al. Does ASPA gene mutation in Canavan disease alter oligodendrocyte development? A tissue culture study of ASPA KO mice brain. N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System 2006, 175-182. Springer Science + Business Media, New York. J.R. Moffett, S.B. Tieman, D.R. Weinberger, J.T. Coyle, M.A. Namboodiri (Eds.).
80. Ledeen R.W. Lipid-metabolizing enzymes of myelin and their relation to the axon. Journal of Lipid Research 1984, 25:1548-1554.
81. Leone P., Shera D., McPhee S.W., Francis J.S., Kolodny E.H., Bilaniuk L.T., et al. Long-term follow-up after gene therapy for canavan disease. Science Translational Medicine 2012, 4. 165ra163.
82. Lin W., Popko B. Endoplasmic reticulum stress in disorders of myelinating cells. Nature Neuroscience 2009, 12:379-385.
83. Lindner H., Hopfner S., Tafler-Naumann M., Miko M., Konrad L., Rohm K.H. The distribution of aminoacylase I among mammalian species and localization of the enzyme in porcine kidney. Biochimie 2000, 82:129-137.
84. Luthi-Carter R., Barczak A.K., Speno H., Coyle J.T. Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Research 1998, 795:341-348.
85. MacDonald J.L., Roskams A.J. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Progress in Neurobiology 2009, 88:170-183.
86. Madhavarao C.N., Arun P., Moffett J.R., Szucs S., Surendran S., Matalon R., et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proceedings of the National Academy of Sciences USA 2005, 102:5221-5226.
87. Madhavarao C.N., Chinopoulos C., Chandrasekaran K., Namboodiri M.A. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. Journal of Neurochemistry 2003, 86:824-835.
88. Madhavarao C.N., Moffett J.R., Moore R.A., Viola R.E., Namboodiri M.A., Jacobowitz D.M. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Journal of Comparative Neurology 2004, 472:318-329.
89. Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with canavan disease. American Journal of Medical Genetics 1988, 29:463-471.
90. Matalon R., Michals-Matalon K. Molecular basis of Canavan disease. European Journal of Paediatric Neurology 1998, 2:69-76.
91. Mattan N.S., Ghiani C.A., Lloyd M., Matalon R., Bok D., Casaccia P., et al. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Neurobiology of Disease 2010, 40:432-443.
92. Mehta V., Namboodiri M.A. N-acetylaspartate as an acetyl source in the nervous system. Molecular Brain Research 1995, 31:151-157.
93. Miyake M., Kakimoto Y. Developmental changes of N-acetyl-l-aspartic acid, N-acetyl-alpha-aspartylglutamic acid and beta-citryl-l-glutamic acid in different brain regions and spinal cords of rat and guinea pig. Journal of Neurochemistry 1981, 37:1064-1067.
94. Miyake M., Kakimoto Y., Sorimachi M. A gas chromatographic method for the determination of N-acetyl-l-aspartic acid, N-acetyl-aspartylglutamic acid and beta-citryl-l-glutamic acid and their distributions in the brain and other organs of various species of animals. Journal of Neurochemistry 1981, 36:804-810.
95. Miyamoto E., Kakimoto Y., Sano I. Identification of N-acetylaspartylglutamic acid in the bovine brain. Journal of Neurochemistry 1966, 13:999-1003.
96. 1H NMR spectroscopy of rat brain in vivo at 14.1Tesla: improvements in quantification of the neurochemical profile. Journal of Magnetic Resonance 2008, 194:163-168.
97. Moffett J.R. Reductions in N-acetylaspartylglutamate and the 67kDa form of glutamic acid decarboxylase immunoreactivities in the visual system of albino and pigmented rats after optic nerve transections. Journal of Comparative Neurology 2003, 458:221-239.
98. Moffett J.R., Arun P., Ariyannur P.S., Garbern J.Y., Jacobowitz D.M., Namboodiri A.M. Extensive aspartoacylase expression in the rat central nervous system. Glia 2011, 59:1414-1434.
99. Moffett J.R., Namboodiri M.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. Journal of Neurocytology 1995, 24:409-433.
100. Moffett J.R., Namboodiri M.A. Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system. N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System 2006, 7-26. Springer Science + Business Media, New York. J.R. Moffett, S.B. Tieman, D.R. Weinberger, J.T. Coyle, M.A. Namboodiri (Eds.).
101. Moffett J.R., Namboodiri M.A., Cangro C.B., Neale J.H. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991, 2:131-134.
102. Moffett J.R., Namboodiri M.A., Neale J.H. Enhanced carbodiimide fixation for immunohistochemistry: Application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. Journal of Histochemistry and Cytochemistry 1993, 41:559-570.
103. 67 immunoreactivities in the cerebellum and precerebellar nuclei of the rat utilizing enhanced carbodiimide fixation and immunohistochemistry. Journal of Comparative Neurology 1994, 347:598-618.
104. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri A.M. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Progress in Neurobiology 2007, 81:89-131.
105. Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., Namboodiri M.A. N-Acetylaspartate: a unique neuronal molecule in the central nervous system 2006, Vol. 576. Springer Science + Business Media, New York.
106. Moffett J.R., Williamson L.C., Palkovits M., Namboodiri M.A. N-acetylaspartylglutamate: a transmitter candidate for the retinohypothalamic tract. Proceedings of the National Academy of Sciences, USA 1990, 87:8065-8069.
107. 13C]glucose infusion. Journal of Neurochemistry 2001, 77:347-350.
108. Nadler J.V., Cooper J.R. Metabolism of the aspartyl moiety of N-acetyl-l-aspartic acid in the rat brain. Journal of Neurochemistry 1972, 19:2091-2105.
109. Nadler J.V., Cooper J.R. N-acetyl-l-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. Journal of Neurochemistry 1972, 19:313-319.
110. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., et al. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-relation to brain concentration. Neuropharmacology 2006, 5:1163-1171.
111. Namboodiri M.A., Corigliano-Murphy A., Jiang G., Rollag M., Provencio I. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Molecular Brain Research 2000, 77:285-289.
112. Neale J.H. N-Acetylaspartylglutamate is an agonist at mGluR3 in vivo and in vitro. Journal of Neurochemistry 2011, 119:891-895.
113. Neale J.H., Bzdega T., Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. Journal of Neurochemistry 2000, 75:443-452.
114. Nicoletti F., Bockaert J., Collingridge G.L., Conn P.J., Ferraguti F., Schoepp D.D., et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011, 60:1017-1041.
115. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology 2010, 50:295-322.
116. Niwa M., Nitta A., Mizoguchi H., Ito Y., Noda Y., Nagai T., et al. A novel molecule "shati" is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference. Journal of Neuroscience 2007, 27:7604-7615.
117. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. Journal of Neurochemistry 2004, 89:876-885.
118. Olszewski R.T., Bzdega T., Neale J.H. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophrenia Research 2012, 136:160-161.
119. Olszewski R.T., Janczura K.J., Ball S.R., Madore J.C., Lavin K.M., Lee J.C., et al. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Translational Psychiatry 2012, 2:e145.
120. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Molecular and Chemical Neuropathology 1997, 31:97-118.
121. Passani L.A., Vonsattel J.P., Coyle J.T. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Research 1997, 772:9-22.
122. Patel T.B., Clark J.B. Synthesis of N-acetyl-l-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochemical Journal 1979, 184:539-546.
123. Perrier J., Durand A., Giardina T., Puigserver A. Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie 2005, 87:673-685.
124. Ramos M., Pardo B., Llorente-Folch I., Saheki T., Del A.A., Satrustegui J. Deficiency of the mitochondrial transporter of aspartate/glutamate aralar/AGC1 causes hypomyelination and neuronal defects unrelated to myelin deficits in mouse brain. Journal of Neuroscience Research 2011, 89:2008-2017.
125. Reichelt K.L., Kvamme E. Acetylated and peptide bound glutamate and aspartate in brain. Journal of Neurochemistry 1967, 14:987-996.
126. Renno W.M., Lee J.H., Beitz A.J. Light and electron microscopic immunohistochemical localization of N-acetylaspartylglutamate (NAAG) in the olivocerebellar pathway of the rat. Synapse 1997, 26:140-154.
127. 1H magnetic resonance spectroscopy at 3 T in cryptogenic and mesial temporal lobe epilepsy. NMR in Biomedicine 2006, 19:544-553.
128. Rigotti D., Gass A., Achtnichts L., Inglese M., Babb J., Naegelin Y., et al. Multiple sclerosis severity scale and whole-brain N-acetylaspartate concentration for patients' assessment. Multiple Sclerosis 2011, 18:98-107.
129. Rigotti D.J., Inglese M., Babb J.S., Rovaris M., Benedetti B., Filippi M., et al. Serial whole-brain N-acetylaspartate concentration in healthy young adults. American Journal of Neuroradiology 2007, 28:1650-1651.
130. Rigotti D.J., Kirov I.I., Djavadi B., Perry N., Babb J.S., Gonen O. Longitudinal whole-brain N-acetylaspartate concentration in healthy adults. American Journal of Neuroradiology 2011, 32:1011-1015.
131. Riveros N., Orrego F. A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations. Brain Research 1984, 299:393-395.
132. Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. Journal of Biological Chemistry 1987, 262:14498-14506.
133. Romei C., Raiteri M., Raiteri L. Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG). Neuropharmacology 2012, 66:311-316.
134. Sacha P., Zamecnik J., Barinka C., Hlouchova K., Vicha A., Mlcochova P., et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007, 144:1361-1372.
135. Sangar M.C., Bansal S., Avadhani N.G. Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opinion Drug Metabolism and Toxicology 2010, 6:1231-1251.
136. 2+ signaling in neuronal mitochondria. Journal of Neuroscience Research 2007, 85:3359-3366.
137. Savic I., Lekvall A., Greitz D., Helms G. MR spectroscopy shows reduced frontal lobe concentrations of N-acetyl aspartate in patients with juvenile myoclonic epilepsy. Epilepsia 2000, 41:290-296.
138. Savic I., Osterman Y., Helms G. MRS shows syndrome differentiated metabolite changes in human-generalized epilepsies. Neuroimage 2004, 21:163-172.
139. Signoretti S., Lazzarino G., Tavazzi B., Vagnozzi R. The pathophysiology of concussion. PM R 2011, 3:S359-S368.
140. Signoretti S., Vagnozzi R., Tavazzi B., Lazzarino G. Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications. Neurosurgical Focus 2010, 29:E1.
141. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991, 45:37-45.
142. Sistermans E.A., de Coo R.F., van Beerendonk H.M., Poll-The BT, Kleijer W.J., van Oost B.A. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population. European Journal of Human Genetics 2000, 8:557-560.
143. Soupart A., Schroeder B., Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrology Dialysis Transplantation 2007, 22:1856-1863.
144. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. International Journal of Biochemistry and Cell Biology 2009, 41:185-198.
145. Surendran S., Campbell G.A., Tyring S.K., Matalon R. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. Neurobiology of Disease 2005, 18:385-389.
146. Suwanwelaa N., Phanuphak P., Phanthumchinda K., Suwanwela N.C., Tantivatana J., Ruxrungtham K., et al. Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magnetic Resonance Imaging 2000, 18:859-865.
147. Tahay G., Wiame E., Tyteca D., Courtoy P.J., Van S.E. Determinants of the enzymatic activity and the subcellular localization of aspartate N-acetyltransferase. Biochemical Journal 2012, 441:105-112.
148. Takatsu Y., Fujita Y., Tsukamoto T., Slusher B.S., Hashimoto K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Research 2011, 1371:82-86.
149. Tallan H.H. Studies on the distribution of N-acetyl-L-aspartic acid in brain. Journal of Biological Chemistry 1957, 224:41-45.
150. Tallan H.H., Moore S., Stein W.H. N-Acetyl-L-aspartic acid in brain. Journal of Biological Chemistry 1956, 219:257-264.
151. Taylor D.L., Davies S.E., Obrenovitch T.P., Doheny M.H., Patsalos P.N., Clark J.B., et al. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. Journal of Neurochemistry 1995, 65:275-281.
152. Taylor D.L., Davies S.E., Obrenovitch T.P., Urenjak J., Richards D.A., Clark J.B., et al. Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. Journal of Neurochemistry 1994, 62:2349-2355.
153. Thomas A.G., Corse A.M., Coccia C.F., Bilak M.M., Rothstein J.D., Slusher B.S. NAALADase inhibition protects motor neurons against chronic glutamate toxicity. European Journal of Pharmacology 2003, 471:177-184.
154. Tieman S.B. Cellular localization of NAAG. N-Acetylaspartate: A unique neuronal molecule in the central nervous system 2006, 289-301. Springer Science + Business Media, New York, NY. J.R. Moffett, S.B. Tieman, D.R. Weinberger, J.T. Coyle, M.A. Namboodiri (Eds.).
155. Tieman S.B., Cangro C.B., Neale J.H. N-acetylaspartylglutamate immunoreactivity in neurons of the cat's visual system. Brain Research 1987, 420:188-193.
156. Tieman S.B., Moffett J.R., Irtenkauf S.M. Effect of eye removal on N-acetylaspartylglutamate immunoreactivity in retinal targets of the cat. Brain Research 1991, 562:318-322.
157. Tieman S.B., Neale J.H., Tieman D.G. N-acetylaspartylglutamate immunoreactivity in neurons of the monkey's visual pathway. Journal of Comparative Neurology 1991, 313:45-64.
158. Tieman S.B., Tieman D.G. N-acetylaspartylglutamate immunoreactivity in human retina. Vision Research 1996, 36:941-947.
159. Traeger E.C., Rapin I. The clinical course of Canavan disease. Pediatric Neurology 1998, 18:207-212.
160. Traka M., Wollmann R.L., Cerda S.R., Dugas J., Barres B.A., Popko B. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Journal of Neuroscience 2008, 28:11537-11549.
161. Truckenmiller M.E., Namboodiri M.A., Brownstein M.J., Neale J.H. N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. Journal of Neurochemistry 1985, 45:1658-1662.
162. Tsai G., Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology 1995, 46:531-540.
163. Tsai G., Forloni G.L., Robinson M.B., Stauch B.L., Coyle J.T. Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. Journal of Neurochemistry 1988, 51:1956-1959.
164. Tsukamoto T., Wozniak K.M., Slusher B.S. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discovery Today 2007, 12:767-776.
165. Urenjak J., Williams S.R., Gadian D.G., Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. Journal of Neurochemistry 1992, 59:55-61.
166. Vagnozzi R., Signoretti S., Cristofori L., Alessandrini F., Floris R., Isgro E., et al. Assessment of metabolic brain damage and recovery following mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic study in concussed patients. Brain 2010, 133:3232-3242.
167. van Bogaert L., Bertrand I. Sur une idiotie familiale avec degerescence sponglieuse de neuraxe (note preliminaire). Acta Neurology 1949, 49:572-587.
168. Verbalis J.G. Control of Brain Volume During Hypoosmolality and Hyperosmolality. N-Acetylaspartate: A unique neuronal molecule in the central nervous system 2006, 113-129. Springer Science + Business Media, New York, NY. J.R. Moffett, S.B. Tieman, D.R. Weinberger, J.T. Coyle, M.A. Namboodiri (Eds.).
169. Wang J., Matalon R., Bhatia G., Wu G., Li H., Liu T., et al. Bimodal occurrence of aspartoacylase in myelin and cytosol of brain. Journal of Neurochemistry 2007, 101:448-457.
170. Wardlaw J.M., Marshall I., Wild J., Dennis M.S., Cannon J., Lewis S.C. Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome. Stroke 1998, 29:1618-1624.
171. Watanabe T., Shiino A., Akiguchi I. Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dementia and Geriatric Cognitive Disorders 2010, 30:71-77.
172. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
173. Westbrook G.L., Mayer M.L., Namboodiri M.A., Neale J.H. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. Journal of Neuroscience 1986, 6:3385-3392.
174. Wiame E., Tyteca D., Pierrot N., Collard F., Amyere M., Noel G., et al. Molecular Identification of Aspartate N-acetyltransferase and its Mutation in Hypoacetylaspartia. Biochemistry Journal 2010, 425:127-136.
175. Wibom R., Lasorsa F.M., Tohonen V., Barbaro M., Sterky F.H., Kucinski T., et al. AGC1 deficiency associated with global cerebral hypomyelination. New England Journal of Medicine 2009, 361:489-495.
176. Williamson L.C., Eagles D.A., Brady M.J., Moffett J.R., Namboodiri M.A., Neale J.H. Localization and synaptic release of N-acetylaspartylglutamate in the chick retina and optic tectum. European Journal of Neuroscience 1991, 3:441-451.
177. Williamson L.C., Neale J.H. Ultrastructural localization of N-acetylaspartylglutamate in synaptic vesicles of retinal neurons. Brain Research 1988, 456:375-381.
178. Williamson L.C., Neale J.H. Uptake, metabolism, and release of N-[3H]acetylaspartylglutamate by the avian retina. Journal of Neurochemistry 1992, 58:2191-2199.
179. Wittsack H.J., Kugel H., Roth B., Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. Journal of Magnetic Resonance Imaging 1996, 6:889-893.
180. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196:431-440.
181. Wozniak K.M., Rojas C., Wu Y., Slusher B.S. The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Current Medicinal Chemistry. 2012, 19:1323-1334.
182. Wroblewska B., Wroblewski J.T., Saab O.H., Neale J.H. N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. Journal of Neurochemistry 1993, 61:943-948.
183. Yamada T., Zuo D., Yamamoto T., Olszewski R.T., Bzdega T., Moffett J.R., et al. NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Molecular Pain 2012, 8:67.
184. Yamashita H., Kaneyuki T., Tagawa K. Production of acetate in the liver and its utilization in peripheral tissues. Biochimica Biophysica Acta 2001, 1532:79-87.
185. Ye F., Chen Y., Hoang T., Montgomery R.L., Zhao X.H., Bu H., et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nature Neuroscience 2009, 12:829-838.
186. Zano S., Wijayasinghe Y.S., Malik R., Smith J., Viola R.E. Relationship between enzyme properties and disease progression in Canavan disease. Journal of Inherited Metabolic Disease 2012, 36:1-6.
187. Zeng B.J., Wang Z.H., Ribeiro L.A., Leone P., De Gasperi R., Kim S.J., et al. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. Journal of Inherited Metabolic Disease 2002, 25:557-570.
188. Zhang W., Murakawa Y., Wozniak K.M., Slusher B., Sima A.A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. Journal of the Neurological Sciences 2006, 247:217-223.
189. Zhang W., Slusher B., Murakawa Y., Wozniak K.M., Tsukamoto T., Jackson P.F., et al. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. Journal of the Neurological Sciences 2002, 194:21-28.
190. Zhao J., Ramadan E., Cappiello M., Wroblewska B., Bzdega T., Neale J.H. NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. European Journal of Neuroscience 2001, 13:340-346.
191. Zhong C., Zhao X., Van K.C., Bzdega T., Smyth A., Zhou J., et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. Journal of Neurochemistry 2006, 97:1015-1025.
192. Zollinger M., Brauchli-Theotokis J., Gutteck-Amsler U., Do K.Q., Streit P., Cuenod M. Release of N-acetylaspartylglutamate from slices of rat cerebellum, striatum, and spinal cord, and the effect of climbing fiber deprivation. Journal of Neurochemistry 1994, 63:1133-1142.
193. Zuo D., Bzdega T., Olszewski R.T., Moffett J.R., Neale J.H. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in the prefrontal cortex and nucleus accumbens in the phencyclidine model of schizophrenia. Journal of Biological Chemistry 2012, 287:21773-21782.